YUMAB and ISAR Bioscience Collaborate to Develop a Novel Transferrin Receptor Antibody Platform for Delivering Therapeutics Across Blood-Brain Barrier.
YUMAB GmbH (“YUMAB”), a leading antibody discovery contract research organization headquartered in Braunschweig, Germany, and ISAR Bioscience GmbH (“ISAR Bioscience”), a regenerative and translational medicine driven company based in Planegg, Germany, announced their collaboration to develop a novel transferrin receptor (TfR) specific antibody for the delivery of biotherapeutics across the blood brain barrier (BBB).
ISAR Bioscience is an expert in developing innovative therapies for (neuro-)degenerative and immune diseases while YUMAB has a proven track record in antibody discovery, engineering and manufacturing.
Both teams share a common vision of overcoming the restrictive nature of the blood-brain-barrier (BBB) to enable more effective treatments for diseases of the central nervous system (CNS) agents.
They will join forces to exploit the transferrin receptor (TfR) pathway and develop a platform based on a TfR-specific antibody capable of transporting a broad range of cargos across the BBB enabling a non-invasive transport of agents into the CNS.
Contact
YUMAB GmbH
Dr. Thomas Schirrmann
info@yumab.com